Significance of GATA3 expression in triple-negative breast cancers
Research type
Research Study
Full title
The significance of GATA3 expression in triple-negative breast carcinomas and utility in a panel for a tumour of an unknown primary
IRAS ID
200082
Contact name
Lisa-Marie Newlove
Contact email
Sponsor organisation
Barking, Havering and Redbridge University Hospitals NHS Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Identifying GATA3 as a useful marker as part of a panel for a tumour of an unknown primary will greatly benefit diagnosis. Currently, the only breast marker used on the panel is ER; This is even though only 70% of breast cancer patients express the antigen, and the antibody isn’t specific, staining other carcinomas such as ovarian. Expression of GATA3 is specific to breast and urothelial carcinomas, narrowing the cell-line possibility and therefore aiding a more accurate diagnosis.
I intend to evaluate the expression of GATA3 in triple-negative (ER, PR and HER2-negative) breast carcinomas, comparing this marker with other common breast markers, GCDFP15 and Mammaglobin. I will then discuss the worth of GATA3 expression in relation to including the marker as part of a panel of antibodies used to determine the origin of a tumour of an unknown primary. As well as this, the project will allow me to discuss future patient management and the potential for development of a novel therapeutic approach.
A sample size of 100 will be used; this number will provide good statistical analysis and therefore a confident conclusion can be made based on the results of this study.REC name
East of England - Essex Research Ethics Committee
REC reference
16/EE/0104
Date of REC Opinion
18 Mar 2016
REC opinion
Further Information Favourable Opinion